Novanta Inc. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone fourth-quarter filing; the filing also provides unaudited quarterly results. All amounts are U.S. dollars.
Business context
Novanta supplies precision technology components and subsystems to medical and advanced industrial OEMs. Its reportable segments are Photonics, Vision and Precision Motion. Medical sales represented approximately 55% of 2019 revenue, up from 50% in 2018; advanced industrial sales represented 45%. No customer accounted for more than 10% of revenue.
Financial performance
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $626.1 million | $614.3 million | +1.9% |
| Gross profit / margin | $262.1 million / 41.9% | $261.5 million / 42.6% | Margin down 0.7 percentage points |
| Operating income / margin | $55.3 million / 8.8% | $71.0 million / 11.6% | Down 22.2%; margin down 2.8 points |
| Net income attributable to Novanta | $40.8 million | $49.1 million | Down 17.0% |
| Diluted EPS | $1.15 | $1.43 | Down $0.28 |
| Cash from operating activities | $63.2 million | $89.6 million | Down $26.4 million |
2019 revenue growth reflected stronger medical demand, partly offset by weaker advanced industrial demand. Acquisitions contributed $17.4 million of revenue, while foreign exchange reduced revenue by $9.8 million. Operating income declined chiefly as restructuring and acquisition-related costs increased and R&D spending rose.
Fourth quarter: Revenue was $159.7 million versus $156.2 million in Q4 2018. Operating income was $13.0 million versus $15.7 million; net income attributable to Novanta was $9.2 million versus $11.6 million. Diluted EPS was $0.26 versus $0.33.
Segments: Photonics revenue fell 7.6% to $230.5 million and operating income fell to $42.0 million from $59.3 million. Vision revenue rose 16.5% to $271.4 million and operating income rose to $21.0 million from $9.0 million. Precision Motion revenue fell 6.0% to $124.2 million and operating income fell to $22.3 million from $31.7 million.
Cash, debt and liquidity
- Year-end cash and cash equivalents were $78.9 million, compared with $82.0 million a year earlier.
- Gross borrowings under the senior credit facilities were approximately $224.6 million; the balance sheet reported debt net of financing costs. Unused revolver capacity was $226.6 million.
- The December 2019 refinancing established $100 million equivalent euro-denominated term debt and a $350 million revolving facility, both maturing in December 2024. The reported leverage ratio was 1.88 against a maximum of 3.50; fixed-charge coverage was 5.35 against a minimum of 1.50.
- Cash used in investing activities was $63.8 million, including $53.1 million net cash for acquisitions and $10.7 million of capital expenditures. Financing activities used $3.9 million net.
- Management said operating cash flow and available liquidity should cover operating and capital needs for at least the next 12 months. Planned 2020 capital expenditures were approximately $18–$21 million.
Material changes, outlook and notable items
- 2019 acquisitions: ARGES for $72.9 million, Med X Change for $21.9 million and Ingenia for $16.2 million. ARGES included $27.4 million of deferred cash consideration and contingent consideration; deferred payments from 2018–2019 acquisitions were expected to be paid in 2020.
- Restructuring and acquisition-related costs rose to $16.6 million from $8.0 million. The company expected to complete its restructuring programs in Q1 2020, with $0.1–$0.2 million of additional charges anticipated for each of the 2018 and 2019 programs.
- The 2019 effective tax rate was 10.9%, compared with 16.7% in 2018, reflecting jurisdictional income mix and tax benefits including U.K. patent box deductions, share-based compensation and tax credits.
- The board authorized a further $50 million share-repurchase plan in February 2020, after the 2018 plan. The company had never paid cash dividends and did not anticipate doing so in the foreseeable future.
- No formal revenue or earnings guidance is provided in the filing. Management cited continuing weakness in advanced industrial markets. The filing also noted the emerging coronavirus disruption: Novanta’s Suzhou facility was briefly closed and reopened in February 2020; near- and longer-term effects remained uncertain, with potential supply, labor and demand impacts.
Other material exposures include cyclical OEM capital spending, tariffs and trade restrictions, foreign exchange and variable interest rates, single-source components, acquisition integration and valuation risk, medical-device regulation, cybersecurity and privacy compliance, and potential impairment of goodwill and intangible assets. The company reported $440.9 million of goodwill and net intangible assets and no impairment in 2019. It reported ordinary-course legal claims but did not expect them to have a material adverse effect; it cautioned that outcomes cannot be assured.
Important facts for investors to verify
- Whether advanced industrial demand stabilized after the 2019 downturn, and how much of revenue growth was organic versus acquisition-driven.
- Whether Vision’s growth and margin improvement persist, and whether Photonics and Precision Motion recover their revenue and operating profitability.
- Cash conversion and working capital: operating cash flow declined, days sales outstanding increased to 54 from 51, and inventory turnover fell to 3.1 from 3.4.
- Acquisition integration, the performance of ARGES, Med X Change and Ingenia, and the ultimate cash cost of deferred and contingent consideration.
- Debt repayment capacity, covenant headroom, and sensitivity to interest rates; management estimated a 100-basis-point rate increase would add about $2.2 million to annual pretax interest expense.
- Coronavirus-related operating and supply-chain impacts, restructuring completion and costs, and progress against the stated 2020 capital-spending range.